secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107471
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026
-------------------------------------------------------------------------

- Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.
- 100 patients enrolled, 80 completed in Halneuron Phase 2b trial; interim analysis on track for Q4 2025.
- Secured exclusive worldwide royalty-free license to develop SP16 for cancer-related pain via all-stock transaction.
- Cash and equivalents of $10.1M expected to fund operations into Q1 2026.
- SP16 Phase 1b study fully funded by National Cancer Institute; FDA feedback anticipated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/0001104659-25-107471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/dwtx-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer